ArticleBMC cancer2013
Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01795274 (Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer.Radiation oncology (London, England) · 2015Trial
- Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outcome.Frontiers in oncology · 2026Article
- An adaptive planning strategy in carbon ion therapy of pancreatic cancer involving beam angle selection.Physics and imaging in radiation oncology · 2022Article
- Heavy charged particles for gastrointestinal cancers.Journal of gastrointestinal oncology · 2020Review
- Review
- Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States.International journal of particle therapy · 2020Article
- Carbon Ion Therapy: A Modern Review of an Emerging Technology.Frontiers in oncology · 2020Review
- A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.Medicine · 2019Article
- Significance of intra-fractional motion for pancreatic patients treated with charged particles.Radiation oncology (London, England) · 2018Article
- Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair.Cancers · 2017Review
- Planning strategies for inter-fractional robustness in pancreatic patients treated with scanned carbon therapy.Radiation oncology (London, England) · 2017Article
- The Emerging Role of Carbon-Ion Radiotherapy.Frontiers in oncology · 2016Article
- Article
- Article
- Robustness of target dose coverage to motion uncertainties for scanned carbon ion beam tracking therapy of moving tumors.Physics in medicine and biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment options for patients with locally advanced pancreatic cancer include surgery, chemotherapy as well as radiotherapy. In many cases, surgical resection is not possible, and therefore treatment alternatives have to be performed. Chemoradiation has been established as a convincing treatment alternative for locally advanced pancreatic cancer. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 1.16 and 2.46 depending on the pancreatic cancer cell line as well as the endpoint analyzed. Japanese Data on the evaluation of carbon ion radiation therapy showed promising results for patients with pancreatic cancer. METHODS AND
designThe present PHOENIX-01 trial evaluates carbon ion radiotherapy using the active rasterscanning technique in patients with advanced pancreatic cancer in combination with weekly gemcitabine and adjuvant gemcitabine. Primary endpoint is toxicity, secondary endpoints are overall survival, progression-free survival and response. DISCUSSION: The physical and biological properties of the carbon ion beam promise to improve the therapeutic ratio in patients with pancreatic cancer: Due to the inverted dose profile dose deposition in the entry channel of the beam leads to sparing of normal tissue; the Bragg peak can be directed into the defined target volume, and the sharp dose fall-off thereafter again spares normal tissue behind the target volume. The higher RBE of carbon ions, which has been shown also for pancreatic cancer cell lines in the preclinical setting, is likely to contribute to an increase in local control, and perhaps in OS. Early data from Japanese centers have shown promising results. In conclusion, this is the first trial to evaluate actively delivered carbon ion beams in patients with locally advanced pancreatic cancer within a dose-escalation strategy.
trial registrationNCT01795274.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.